US3043745A - Allantoin and coal tar extract composition and treatment of psoriasis - Google Patents
Allantoin and coal tar extract composition and treatment of psoriasis Download PDFInfo
- Publication number
- US3043745A US3043745A US858870A US85887059A US3043745A US 3043745 A US3043745 A US 3043745A US 858870 A US858870 A US 858870A US 85887059 A US85887059 A US 85887059A US 3043745 A US3043745 A US 3043745A
- Authority
- US
- United States
- Prior art keywords
- psoriasis
- allantoin
- coal tar
- treatment
- tar extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
- A61K35/04—Tars; Bitumens; Mineral oils; Ammonium bituminosulfonate
Definitions
- the present invention relates to an improved method for the treatment of psoriasis.
- This application is a continuation-in-part of co-pending application Serial No. 714,482, filed February 11, 1958, now abandoned.
- Psoriasis is a highly important dermatosis. It has an incidence of between 1% and 2% of the total population, and its lesions are of recurrent nature and usually very resistant to therapy. The lesions are usually numerous and are characteristically silvery gray scaling papulas or plaques with an underlying redness which most frequently occur in the scalp, elbows, knees and lumbosacral region. The etiology of the disease is at present completely unknown, although it is non-infectious and believed to be the result of a metabolic deficiency.
- Another object of the present invention is to provide an improved method for the treatment of psoriasis which does not unduly incapacitate or inconvenience the patient.
- Still another object of the present invention is to provide an improved simple and inexpensive method for the treatment of psoriasis.
- the present invention is based on the discovery that the topical application to a psoriasis-afilicted area of a medication containing a predetermined concentration of allantoin and coal tar extract is followed by a relatively prompt disappearance of the gross scaling followed by a radical reduction in or the disappearance of the redness and lesions. As long as the medication is applied, the characteristic symptoms of the psoriasis will not return. The treatment may be safely continued until the disease completely subsides.
- the allantoin should be present in concentrations exceeding /z% and preferably in excess of 1% and more particularly in concentrations of between 2% and and the coal tar extract should be present in a concentration exceeding 1% and preferably should be between 1% and 10%.
- Scaling is constantly present and occuring in the normal epidermis but the size of the scales are so minute that they are not usually observable or unsightly. In the case of psoriasis, however, the scales are gross and unsightly.
- a chemical analysis of the psoriasis scales as compared to the normal epidermis scale indicates that the water soluble fraction of the psoriasis scale is low in its free amino nitrogen content and high in its sulfhydryl content.
- the application of the allantoin to the psoriasis-aifiicted area results in the epidermis returning, at least superficially, to its normal scaling activity.
- the lotion is prepared by mixing the polyethylene glycol monostearate, isopropyl palmitate, stearic acid, N.F., propylene glycol and coal tar extract (liquor carbonis detergens) in a suitable jacketed kettle. The mixture is then heated to; C. with stirring until all the ingredients are melted and then the water, at 80 C., is added and mixing continued until an emulsion is obtained, the mixing time being approximately thirty minutes. The emulsion is then cooled to 40 C. and the allantoin added with gentle agitation, the mixing being continued until the lotion has cooled to room temperature.
- the allantoin should preferably be in solution in the lotion or in the form of a fine suspension in whichthe allantoin particle size averages about 200 microns or smaller.
- the allantoin should constitute at least /2% by Weight of the lotion and preferably between 2% and 10% by weight.
- the coal tar extract should be present in amounts of between 1% and 10% by weight of the lotion.
- the amounts of polyethylene glycol monostearate, isopropyl palmitate, ste'aric acid and propylene glycol may be varied within ranges which will produce a stable lotion with the all-antoin at the above concentration and in solution or in a fine uniform colloidal dispersion.
- suitable substitutes may be employed in place of some of the ingredients, for example, polyethylene glycol monostearate of higher molecular weight my be substituted.
- Other materials such as cetyl alcohol, lanolin or lanolin alcohols, or other emulsified fatty acids may be used. It should, of course, be noted that promptly following the application of the medication most of the water evaporates leaving the allantoin, coal tar extract and other ingredients present in correspondingly greater concentrations.
- the lotion specifically set forth above Has been employed clinically and has proven unexpectedly and remarkably effective.
- the lotion was topically applied as a thin layer to the psoriasis-afilicted areas of thirty-two patients between two and four times daily.
- a prompt clearing of the typical psoriatic scale occurred during the first week of treatment.
- the underlying redness was either materially lessened or completely disappeared so that the skin assumed its normal appearance. No peeling accompanied the treatment.
- the psoriasis completely cleared and there was no recurrence for two months after the cessation ofthe treatment.
- sixteen were concurrently given supplementary ultraviolet light treatment, but there was no difference in their response as compared to those who were treated with the lotion alone.
- the area treated by the ointmentcontaining the coal tar extract and the allantoin subsequently exhibited a complete absence of skin lesions or only diminished sealing and mild pruritis; the areas treated with the ointment lacking the allantoin subsequently exhibited atbest only a slight iInprovement and in some cases an aggregation of the symptoms, and the areas treated by the ointment lacking the coal tar extract, on the average, showed no improveemnt' whatsoever.
- An improved medicament for the treatment of psoriasis comprising a composition applicable to a psoriasis-afflicted "area and including a cooperating mixture of at least /2% by weight of allantoin and at least 1% by weight of coal tar extract.
- An improved medicament for the treatment of psoriasis comprising the following ingredients in substantially the designated percentages by weight:
Description
The present invention relates to an improved method for the treatment of psoriasis. This application is a continuation-in-part of co-pending application Serial No. 714,482, filed February 11, 1958, now abandoned.
Psoriasis is a highly important dermatosis. It has an incidence of between 1% and 2% of the total population, and its lesions are of recurrent nature and usually very resistant to therapy. The lesions are usually numerous and are characteristically silvery gray scaling papulas or plaques with an underlying redness which most frequently occur in the scalp, elbows, knees and lumbosacral region. The etiology of the disease is at present completely unknown, although it is non-infectious and believed to be the result of a metabolic deficiency.
There is at present no known permanent cure for psoriasis, although there are several treatments which are transitory and only occasionally eifective, completely losing their usefulness after repeated application. The general effect of these treatments is either merely to physically cover the afliicted areas or to cause a peeling o of the skin. Typical of these treatments, which requires from ten to thirty days, is the application of crude coal tar ointment to the afiected area three times daily, daily ultraviolet exposure to the point of producing a transient erythema followed by prolonged tub baths. It is thus apparent that there is no satisfactory, simple and convenient method for the treatment of psoriasis.
it is, therefore, a principal object of the present invention to provide an improved method for the treatment of psoriasis.
Another object of the present invention is to provide an improved method for the treatment of psoriasis which does not unduly incapacitate or inconvenience the patient.
Still another object of the present invention is to provide an improved simple and inexpensive method for the treatment of psoriasis.
The present invention is based on the discovery that the topical application to a psoriasis-afilicted area of a medication containing a predetermined concentration of allantoin and coal tar extract is followed by a relatively prompt disappearance of the gross scaling followed by a radical reduction in or the disappearance of the redness and lesions. As long as the medication is applied, the characteristic symptoms of the psoriasis will not return. The treatment may be safely continued until the disease completely subsides. The allantoin should be present in concentrations exceeding /z% and preferably in excess of 1% and more particularly in concentrations of between 2% and and the coal tar extract should be present in a concentration exceeding 1% and preferably should be between 1% and 10%.
Scaling is constantly present and occuring in the normal epidermis but the size of the scales are so minute that they are not usually observable or unsightly. In the case of psoriasis, however, the scales are gross and unsightly. A chemical analysis of the psoriasis scales as compared to the normal epidermis scale indicates that the water soluble fraction of the psoriasis scale is low in its free amino nitrogen content and high in its sulfhydryl content. The application of the allantoin to the psoriasis-aifiicted area results in the epidermis returning, at least superficially, to its normal scaling activity. It is believed that under normal scaling conditions the protein depolymerizes 2 to form minute scales and that the necessary depolymerization is absent in the case of psoriasis. It is further believed that the application of the allantoin to the afiiicted areas promotes the necessary depolymerization so that. the resulting scales are of normal minute size.
I The mechanisms and function of the coal tar extract is not clearly understood, but when used with the allantoin there is a pronounced cooperatively produced activity insofar as the treaatment of psoriasis is concerned.
'A specific example of a lotion which has proven to be highly effective is as follows.
Perfume (if desired), q.s.
The lotion is prepared by mixing the polyethylene glycol monostearate, isopropyl palmitate, stearic acid, N.F., propylene glycol and coal tar extract (liquor carbonis detergens) in a suitable jacketed kettle. The mixture is then heated to; C. with stirring until all the ingredients are melted and then the water, at 80 C., is added and mixing continued until an emulsion is obtained, the mixing time being approximately thirty minutes. The emulsion is then cooled to 40 C. and the allantoin added with gentle agitation, the mixing being continued until the lotion has cooled to room temperature. The allantoin should preferably be in solution in the lotion or in the form of a fine suspension in whichthe allantoin particle size averages about 200 microns or smaller.
The allantoin should constitute at least /2% by Weight of the lotion and preferably between 2% and 10% by weight. The coal tar extract should be present in amounts of between 1% and 10% by weight of the lotion. The amounts of polyethylene glycol monostearate, isopropyl palmitate, ste'aric acid and propylene glycol may be varied within ranges which will produce a stable lotion with the all-antoin at the above concentration and in solution or in a fine uniform colloidal dispersion. Furthermore, suitable substitutes may be employed in place of some of the ingredients, for example, polyethylene glycol monostearate of higher molecular weight my be substituted. Other materials such as cetyl alcohol, lanolin or lanolin alcohols, or other emulsified fatty acids may be used. It should, of course, be noted that promptly following the application of the medication most of the water evaporates leaving the allantoin, coal tar extract and other ingredients present in correspondingly greater concentrations.
The lotion specifically set forth above Has been employed clinically and has proven unexpectedly and remarkably effective. In one set of tests, the lotion was topically applied as a thin layer to the psoriasis-afilicted areas of thirty-two patients between two and four times daily. In all cases, a prompt clearing of the typical psoriatic scale occurred during the first week of treatment. In from one to four weeks the underlying redness was either materially lessened or completely disappeared so that the skin assumed its normal appearance. No peeling accompanied the treatment. In four cases, the psoriasis completely cleared and there was no recurrence for two months after the cessation ofthe treatment. Of the thirty-two cases, sixteen were concurrently given supplementary ultraviolet light treatment, but there was no difference in their response as compared to those who were treated with the lotion alone. Some patients afflicted with neurodermititis, the symptoms of which are someabove was followed.
times similar to those of psoriasis, were subjected to the same treatment with the lotion but showed no response whatsoever.
In another set of clinical tests, on twenty-six different patients having psoriasis, the same treatment as described In all cases there was a prompt clearance of the scaling and a steady gradual improvement of the red indurated skin surface. Both sets of clinical tests conclusively. demonstrated the radical superiority of the present improved therapy over any therapy previously employed.
The concurrent use of the allantoin and the coal tar extract exhibits pronounced cooperatively produced activity. A group of patients were each contra-laterally treated with the above described ointment containing both the coal tar extract. and the allantoin, a corresponding ointment in which the allantoin was omitted, and a corre-' sponding ointment in which the coal-tar extract was omitted. In each instance, the patient initially had a rather severe case of psoriasis. In each case, the area treated by the ointmentcontaining the coal tar extract and the allantoin subsequently exhibited a complete absence of skin lesions or only diminished sealing and mild pruritis; the areas treated with the ointment lacking the allantoin subsequently exhibited atbest only a slight iInprovement and in some cases an aggregation of the symptoms, and the areas treated by the ointment lacking the coal tar extract, on the average, showed no improveemnt' whatsoever.
While the allantoin coal tar extract medication was applied to the afilicted areas in the form of a lotion, it
should be noted that it may be applied in other forms of vehicles such as, for example, a salve or ointment or the like, the preparation of which, within the limits above set forth, presents no particular difficulty.
Having now described my invention, what I claim and desire to secure by Letters Patent is? tion between 1% and 1 by weight.
4. The method of treating psoriasis in accordance with 4 claim 2, wherein said coal tar extract is at a concentration between 1% and 10% by weight.
5. An improved medicament for the treatment of psoriasis comprising a composition applicable to a psoriasis-afflicted "area and including a cooperating mixture of at least /2% by weight of allantoin and at least 1% by weight of coal tar extract.
6. An improved medicament in accordance with claim 5, wherein said allantoin constitutes between 2% and 10% by weight of the medicament.
7. An improved medicament in accordance with claim 5, wherein said coal tar extract constitutes between 1% and 10% by weight of said medicament.
8. An improved medicament in accordance with claim 5, wherein said allantoin constitutes between 2% and 10% by weight and said coal tar extract between 1% and 10% by weight of said medicament. I
9. An improved medicament in accordance with claim 8, including water and an emulsifying agent.
10. An improved medicament for the treatment of psoriasis comprising the following ingredients in substantially the designated percentages by weight:
Percent Polyethylene glycol monostearate 400 2.5 Isopropyl palmitate 2.5 Stearic acid 3.0 Propylene glycol 10.0 Coal tar extr 5.0 Allantoin 2.0 Water 75.0
References Cited in the file of this patent UNITED STATES PATENTS 2,124,295 Greenbaum July '19, 1938 OTHER REFERENCES
Claims (1)
1. THE METHOD OF TREATING PSORIASIS COMPRISING APPLYING TO THE PSORIASIS-AFFICTED AREA A MEDICAMENT CONTAINING A COOPERATING MIXTURE OF ALLANTION IN A CONCENTRATION BY WEIGHT EXCEEDING 1/2% AND A COAL TAR EXTRACT IN A CONCENTRATION EXCEEDING 1% BY WEIGHT.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US858870A US3043745A (en) | 1959-12-11 | 1959-12-11 | Allantoin and coal tar extract composition and treatment of psoriasis |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US858870A US3043745A (en) | 1959-12-11 | 1959-12-11 | Allantoin and coal tar extract composition and treatment of psoriasis |
Publications (1)
Publication Number | Publication Date |
---|---|
US3043745A true US3043745A (en) | 1962-07-10 |
Family
ID=25329400
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US858870A Expired - Lifetime US3043745A (en) | 1959-12-11 | 1959-12-11 | Allantoin and coal tar extract composition and treatment of psoriasis |
Country Status (1)
Country | Link |
---|---|
US (1) | US3043745A (en) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4102995A (en) * | 1976-05-13 | 1978-07-25 | Westwood Pharmaceuticals Inc. | Tar gel formulation |
FR2405068A1 (en) * | 1977-10-10 | 1979-05-04 | Sauba Lab | Water in oil emulsions for dry skin - contg. vitamin=A, stigmasterol, allantoin, and alpha tocopherol |
US4788061A (en) * | 1985-07-05 | 1988-11-29 | Shore Ronald N | Extended occlusive treatment of skin disorders |
WO2004011013A1 (en) * | 2002-07-25 | 2004-02-05 | Edward Houston | Psoriasis formulation and method of preparation |
WO2006014100A1 (en) * | 2004-08-05 | 2006-02-09 | Martinez Castillejos Guillermo | Pharmaceutical formulation of herbal medicines based on phytolacca americana, alnus acuminata extracts and coal tar for treating and curing psoriasis |
US20070207222A1 (en) * | 2006-03-01 | 2007-09-06 | Tristrata, Inc. | Composition and method for topical treatment of tar-responsive dermatological disorders |
EP2474312A1 (en) * | 2011-01-06 | 2012-07-11 | Lipp Pharma Arzneimittel GmbH | Means for topical treatment of skin ailments |
WO2013155584A1 (en) | 2012-04-20 | 2013-10-24 | Biolab Sanus Farmacêutica Ltda. | Topical pharmaceutical composition, method for producing the topical pharmaceutical composition, use of the topical pharmaceutical composition and method for the topical treatment of psoriasis, atopic dermatitis or chronic eczema |
US9095574B2 (en) | 2010-02-02 | 2015-08-04 | Scioderm, Inc. | Methods of treating psoriasis using allantoin |
US10086664B2 (en) | 2014-08-04 | 2018-10-02 | General Dynamics European Land Systems—Germany GmbH | Floatable land vehicle |
US20190168016A1 (en) * | 2016-02-09 | 2019-06-06 | Luma Therapeutics, Inc. | Methods, compositions and apparatuses for treating psoriasis by phototherapy |
US11154501B2 (en) * | 2019-08-09 | 2021-10-26 | Nanophase Technologies Corporation | Method of enhancing the efficacy and stability of ingredients in suspensions |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2124295A (en) * | 1935-11-09 | 1938-07-19 | Nat Drug Co | Allantoin ointment |
-
1959
- 1959-12-11 US US858870A patent/US3043745A/en not_active Expired - Lifetime
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2124295A (en) * | 1935-11-09 | 1938-07-19 | Nat Drug Co | Allantoin ointment |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4102995A (en) * | 1976-05-13 | 1978-07-25 | Westwood Pharmaceuticals Inc. | Tar gel formulation |
FR2405068A1 (en) * | 1977-10-10 | 1979-05-04 | Sauba Lab | Water in oil emulsions for dry skin - contg. vitamin=A, stigmasterol, allantoin, and alpha tocopherol |
US4788061A (en) * | 1985-07-05 | 1988-11-29 | Shore Ronald N | Extended occlusive treatment of skin disorders |
WO2004011013A1 (en) * | 2002-07-25 | 2004-02-05 | Edward Houston | Psoriasis formulation and method of preparation |
WO2006014100A1 (en) * | 2004-08-05 | 2006-02-09 | Martinez Castillejos Guillermo | Pharmaceutical formulation of herbal medicines based on phytolacca americana, alnus acuminata extracts and coal tar for treating and curing psoriasis |
US20070207222A1 (en) * | 2006-03-01 | 2007-09-06 | Tristrata, Inc. | Composition and method for topical treatment of tar-responsive dermatological disorders |
US20100093827A1 (en) * | 2006-03-01 | 2010-04-15 | Tristrata, Inc. | Method for topical treatment of tar-responsive dermatological disorders |
US9339492B1 (en) | 2010-02-02 | 2016-05-17 | Scioderm, Inc. | Methods of treating psoriasis using allantoin |
US9095574B2 (en) | 2010-02-02 | 2015-08-04 | Scioderm, Inc. | Methods of treating psoriasis using allantoin |
EP2474312A1 (en) * | 2011-01-06 | 2012-07-11 | Lipp Pharma Arzneimittel GmbH | Means for topical treatment of skin ailments |
WO2013155584A1 (en) | 2012-04-20 | 2013-10-24 | Biolab Sanus Farmacêutica Ltda. | Topical pharmaceutical composition, method for producing the topical pharmaceutical composition, use of the topical pharmaceutical composition and method for the topical treatment of psoriasis, atopic dermatitis or chronic eczema |
US10086664B2 (en) | 2014-08-04 | 2018-10-02 | General Dynamics European Land Systems—Germany GmbH | Floatable land vehicle |
US20190168016A1 (en) * | 2016-02-09 | 2019-06-06 | Luma Therapeutics, Inc. | Methods, compositions and apparatuses for treating psoriasis by phototherapy |
US11154501B2 (en) * | 2019-08-09 | 2021-10-26 | Nanophase Technologies Corporation | Method of enhancing the efficacy and stability of ingredients in suspensions |
CN114423424A (en) * | 2019-08-09 | 2022-04-29 | 纳米技术有限公司 | Method for improving efficacy and stability of suspension components |
JP2022543481A (en) * | 2019-08-09 | 2022-10-12 | ナノフェーズ テクノロジーズ コーポレーション | Method for improving efficacy and stability of components in suspension |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4593046A (en) | Method of reducing skin irritation from benzoyl peroxide | |
US4512978A (en) | Dermatological composition useful in the treatment of psoriasis | |
US3988470A (en) | Treatment of palmar and plant disturbed keratosis | |
Sneddon | Adverse effect of topical fluorinated corticosteroids in rosacea | |
EP0129003B1 (en) | Cosmetic and dermatological compositions containing 1-alpha-hydroxycholecalciferol | |
US3984566A (en) | Method of alleviating the symptoms of dandruff | |
US5503825A (en) | Lip balm composition | |
US3920835A (en) | Treatment of disturbed keratinization | |
CA2301009C (en) | Skin care compositions and use | |
US4477469A (en) | Preparations containing methylsulfonylmethane and methods of use and purification | |
US4857321A (en) | Skin ointment | |
US3043745A (en) | Allantoin and coal tar extract composition and treatment of psoriasis | |
GB2057263A (en) | Compositions containing methylsulphonylmethane | |
AU9284098A (en) | Viscous compositions containing carbon dioxide | |
JPH08502976A (en) | Compositions and complexes containing calcium and sulphate, methods for their synthesis, methods of treatment using the same, cosmetic preparations containing the same | |
JPS6016906A (en) | External drug for skin | |
US3978213A (en) | Cosmetic use of cyclic amp and phosphodiesterase inhibitors | |
US4316902A (en) | Therapeutic compositions and vehicles for topical pharmaceuticals | |
US5122533A (en) | Topical pharmaceutical compositions | |
JP2915931B2 (en) | Anti-irritant and desensitizing compositions and methods of use | |
US4543351A (en) | Spironolactone containing composition for combatting acne | |
US5034382A (en) | Topical composition for treating herpes with adenosine | |
US6861062B2 (en) | Skin cream | |
US2666013A (en) | Pruritus therapy | |
JPS6245527A (en) | Preventive and remedy for gray hair |